Swiss Pharmaceuticals & Biotech Mid-Large Cap Stocks

Tecan Group

Market Cap: CHF 1.8b

Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.

Novartis

Market Cap: CHF 191.7b

Researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.

Roche Holding

Market Cap: CHF 219.7b

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.

Bachem Holding

Market Cap: CHF 4.4b

Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.

Cosmo Pharmaceuticals

Market Cap: CHF 1.0b

Focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.

SKAN Group

Market Cap: CHF 1.2b

Provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Europe, the Americas, Asia, and internationally.

Sandoz Group

Market Cap: CHF 20.5b

Develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide.

Galderma Group

Market Cap: CHF 32.4b

Operates as a dermatology company worldwide.

Kuros Biosciences

Market Cap: CHF 932.9m

Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.

Dottikon ES Holding

Market Cap: CHF 4.1b

Manufactures and sells performance chemicals, intermediates, and active pharmaceutical ingredients for the chemical, biotech, and pharmaceutical maceutic industries worldwide.

Lonza Group

Market Cap: CHF 36.5b

Supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.

Siegfried Holding

Market Cap: CHF 3.4b

Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide.

Idorsia

Market Cap: CHF 798.5m

A biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada.